Hasnain Faheem — SEC insider filings

SEC reporting owner CIK 1352620. 36 insider filings on record with FilingPulse; latest filed 2026-11-09.

Transaction summary — filings shown

Covers all 36 filings on record, filed 2020-10-14 to 2026-11-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Gossamer Bio, Inc. (GOSS)President & CEO, Director186 legs · 1,485,788 sh · $3,250,6642 legs · 42,207 sh · $196,47036
Mirati Therapeutics, Inc. (MRTX)Director61 leg · 10,791 sh · $299,990—13
Kura Oncology, Inc. (KURA)Director8—2 legs · 32,682 sh · $291,2208
Aspen Neuroscience, Inc. (ASPE)Executive Chair, Director3——7
Nuvation Bio Inc. (NUVB)Director1——3

Insider filings — Hasnain Faheem

FiledFormIssuerReported transactionsSource
2026-11-094Aspen Neuroscience, Inc. (ASPE)Grant/award (A): 321,672 @ $0EDGAR
2026-11-024Aspen Neuroscience, Inc. (ASPE)Conversion (C): 14,913 · Conversion (C): 14,316 · Conversion (C): 7,120 · Conversion (C): 14,913 (derivative) · Conversion (C): 14,316 (derivative) · Conversion (C): 7,120 (derivative)EDGAR
2026-10-293Aspen Neuroscience, Inc. (ASPE)Holdings only — no transactions reportedEDGAR
2026-08-264Gossamer Bio, Inc. (GOSS)Grant/award (A): 166 (derivative) @ $1,000.00 · Grant/award (A): 5,800,051 (derivative) @ $0EDGAR
2026-06-044Kura Oncology, Inc. (KURA)Grant/award (A): 35,000 (derivative) @ $0EDGAR
2026-03-204Gossamer Bio, Inc. (GOSS)Disposition to issuer (D): 1,680,000 (derivative) · Disposition to issuer (D): 1,540,000 (derivative) · Disposition to issuer (D): 1,312,500 (derivative) · Disposition to issuer (D): 437,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · Disposition to issuer (D): 544,500 (derivative) · +14 moreEDGAR
2026-01-054Gossamer Bio, Inc. (GOSS)Grant/award (A): 280,000 @ $0 · Grant/award (A): 1,680,000 (derivative) @ $0EDGAR
2025-12-104Kura Oncology, Inc. (KURA)Option exercise (M): 10,000 @ $3.12 · Sale (S): 10,000 @ $10.98EDGAR
2025-10-024Gossamer Bio, Inc. (GOSS)Grant/award (A): 437,500 @ $0EDGAR
2025-06-064Kura Oncology, Inc. (KURA)Grant/award (A): 28,500 (derivative) @ $0EDGAR
2025-03-244Kura Oncology, Inc. (KURA)Option exercise (M): 22,682 @ $6.32 · Sale (S): 22,682 @ $8EDGAR
2025-03-064Gossamer Bio, Inc. (GOSS)Grant/award (A): 1,540,000 (derivative) @ $0EDGAR
2024-06-244Gossamer Bio, Inc. (GOSS)Purchase (P): 372,000 @ $0.67EDGAR
2024-06-074Kura Oncology, Inc. (KURA)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2024-03-284Gossamer Bio, Inc. (GOSS)Sale (S): 23,172 @ $1.16EDGAR
2024-01-234Mirati Therapeutics, Inc. (MRTX)Disposition to issuer (D): 8,717 · Disposition to issuer (D): 6,333 · Disposition to issuer (D): 9,702 · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 10,716 (derivative) · Disposition to issuer (D): 10,000 (derivative)EDGAR
2024-01-044Gossamer Bio, Inc. (GOSS)Grant/award (A): 1,312,500 (derivative) @ $0EDGAR
2024-01-034Mirati Therapeutics, Inc. (MRTX)Grant/award (A): 9,702 @ $58.75EDGAR
2023-11-224Gossamer Bio, Inc. (GOSS)Grant/award (A): 437,500 (derivative) @ $0EDGAR
2023-08-144Mirati Therapeutics, Inc. (MRTX)Purchase (P): 10,791 @ $27.80EDGAR
2023-07-264Gossamer Bio, Inc. (GOSS)Grant/award (A): 540,176 @ $1.82 · Grant/award (A): 135,044 (derivative) @ $0.12EDGAR
2023-06-024Kura Oncology, Inc. (KURA)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2023-05-094Gossamer Bio, Inc. (GOSS)Grant/award (A): 750,000 (derivative) @ $0EDGAR
2023-03-224Gossamer Bio, Inc. (GOSS)Purchase (P): 168,683 @ $1.03 · Purchase (P): 269,389 @ $1.20 · Purchase (P): 440,500 @ $1.14 · Grant/award (A): 544,500 (derivative) @ $0EDGAR
2023-01-244Mirati Therapeutics, Inc. (MRTX)Grant/award (A): 6,333 @ $0 · Grant/award (A): 10,716 (derivative) @ $0EDGAR
2022-12-094Gossamer Bio, Inc. (GOSS)Grant/award (A): 544,500 (derivative) @ $0EDGAR
2022-07-154Gossamer Bio, Inc. (GOSS)Purchase (P): 138,696 @ $7.21EDGAR
2022-06-234Kura Oncology, Inc. (KURA)Grant/award (A): 23,000 (derivative) @ $0EDGAR
2022-03-244Gossamer Bio, Inc. (GOSS)Sale (S): 19,035 @ $8.91EDGAR
2022-01-184Mirati Therapeutics, Inc. (MRTX)Grant/award (A): 3,619 @ $0 · Grant/award (A): 5,243 (derivative) @ $0EDGAR
2022-01-104Gossamer Bio, Inc. (GOSS)Grant/award (A): 650,000 (derivative) @ $0EDGAR
2021-06-234Kura Oncology, Inc. (KURA)Grant/award (A): 23,000 (derivative) @ $0EDGAR
2021-03-014Gossamer Bio, Inc. (GOSS)Grant/award (A): 162,500 @ $0 · Grant/award (A): 325,000 (derivative) @ $0EDGAR
2021-02-264Nuvation Bio Inc. (NUVB)Option exercise (M): 25,000 @ $0 · Grant/award (A): 30,000 @ $10 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2021-01-204Mirati Therapeutics, Inc. (MRTX)Grant/award (A): 2,098 @ $0 · Grant/award (A): 3,064 (derivative) @ $0EDGAR
2020-10-144Gossamer Bio, Inc. (GOSS)Purchase (P): 96,520 @ $10.36EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-13 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1352620 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs